[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @OzmosiHealth Ozmosi Ozmosi posts on X about more info, $pph, $xph, $ibb the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1055982930/interactions)  - X Week XXXXXX +95% - X Month XXXXXXX +42% - X Months XXXXXXX +12% - X Year XXXXXXXXX +86% ### Mentions: XX [#](/creator/twitter::1055982930/posts_active)  - X Week XXX -XX% - X Month XXX -XXXX% - X Months XXXXX +27% - X Year XXXXX +68% ### Followers: XXXXX [#](/creator/twitter::1055982930/followers)  - X Week XXXXX +9.10% - X Month XXXXX +11% - X Months XXXXX +24% - X Year XXXXX +42% ### CreatorRank: XXXXXXX [#](/creator/twitter::1055982930/influencer_rank)  ### Social Influence [#](/creator/twitter::1055982930/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [countries](/list/countries) XXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [finance](/list/finance) XXXX% [currencies](/list/currencies) XXXX% [automotive brands](/list/automotive-brands) XXXX% [travel destinations](/list/travel-destinations) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [more info](/topic/more-info) #204, [$pph](/topic/$pph) #1, [$xph](/topic/$xph) #1, [$ibb](/topic/$ibb) #1, [$xbi](/topic/$xbi) #3, [$abvx](/topic/$abvx) 1.6%, [canada](/topic/canada) 0.74%, [$imab](/topic/$imab) 0.61%, [alzheimers](/topic/alzheimers) 0.61%, [$atra](/topic/$atra) #1 **Top accounts mentioned or mentioned by** [@marketwirenews](/creator/undefined) [@salmanfirat2](/creator/undefined) [@john06746191](/creator/undefined) [@stewdomer](/creator/undefined) [@dwill3000](/creator/undefined) [@chrismangum14](/creator/undefined) [@nicolem52807658](/creator/undefined) [@towiu2](/creator/undefined) [@mitchellreed09](/creator/undefined) **Top assets mentioned** [Bitcoin Incognito (XBI)](/topic/$xbi) [SuperRare (RARE)](/topic/$rare) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)](/topic/$rytm) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Krystal Biotech, Inc. Common Stock (KRYS)](/topic/$krys) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Biogen Inc (BIIB)](/topic/$biib) [AstraZeneca PLC (AZN)](/topic/$azn) [Revolution Medicines, Inc. Common Stock (RVMD)](/topic/$rvmd) [Crinetics Pharmaceuticals, Inc. (CRNX)](/topic/$crnx) [Novartis AG (NVS)](/topic/novartis) [Mist (MIST)](/topic/$mist) [AbbVie Inc (ABBV)](/topic/$abbv) [Vir Biotechnology, Inc. Common Stock (VIR)](/topic/$vir) [Halozyme Therapeutics, Inc. (HALO)](/topic/$halo) ### Top Social Posts [#](/creator/twitter::1055982930/posts) --- Top posts by engagements in the last XX hours "$RCUS Arcus Biosciences' Quemliclustat granted Orphan Drug Designation for Pancreatic Cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943294726255579317) 2025-07-10 13:02:22 UTC 2627 followers, XXX engagements "HanchorBio moves forward with global impact of HCB101 immunotherapy. Listed on TPEx. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945476613271150748) 2025-07-16 13:32:24 UTC 2627 followers, XXX engagements "365mc and Raziel Therapeutics partner to expedite RZL-012 development in South Korea. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945099125575573952) 2025-07-15 12:32:24 UTC 2627 followers, XXX engagements "$CRDL TSX:CRDL Cardiol Therapeutics locks database for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620686476021854) 2025-07-22 11:32:11 UTC 2626 followers, XXX engagements "$RHHBY Roche's latest announcement provides an update on the use of astegolimab in treating chronic obstructive pulmonary disease in accordance with Art. XX LR. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947175365182730374) 2025-07-21 06:02:38 UTC 2627 followers, XXX engagements "$NRSN Join Aaron Lazar and NeuroSense CEO Alon Ben-Noon in a live podcast discussing ALS science PrimeC's strategies and community impact. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947643337483112663) 2025-07-22 13:02:11 UTC 2628 followers, XXX engagements "$NGENF TSXV:NGEN NervGen Pharma announces positive results in Phase 1b/2a trial for NVG-291 in Spinal Cord Injury. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1929501554639581480) 2025-06-02 11:33:13 UTC 2623 followers, 1038 engagements "$WALD Waldencast buys Novaestiq Corp. and U.S. rights for Saypha injectable hyaluronic acid gel line under Obagi Medical brand. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947975586250662391) 2025-07-23 11:02:26 UTC 2626 followers, XXX engagements "$BMY Bristol Myers Squibb's sNDA for Sotyktu (deucravacitinib) in treating active Psoriatic Arthritis accepted for review in four regions worldwide. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947250723793866964) 2025-07-21 11:02:05 UTC 2628 followers, XXX engagements "$ATRA Atara Biotherapeutics reports FDA acceptance and priority review of Biologics License Application for Tab-cel to treat EBV+ post-transplant lymphoproliferative disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360684540219405) 2025-07-24 12:32:40 UTC 2630 followers, XXX engagements "WHO adds ArkBio's Ziresovir to list of priority drugs for pediatric RSV. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945295410538619297) 2025-07-16 01:32:22 UTC 2627 followers, XXX engagements "Pharma/Biotech Highlights: $MRNS: Marinus Pharma reports Q4 2023 earnings. $RYTM: Rhythm Pharma screens for obesity treatment. $NWPHF: Evenamide shows promise in treating TRS. $RARE: Ultragenyx's Evkeeza recommended in UK"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1743020790495289398) 2024-01-04 21:25:14 UTC 2627 followers, XXX engagements "Aviva Biopharm Inc. presents new pre-clinical data on d3-T a groundbreaking testosterone therapy for women at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944751814290919756) 2025-07-14 13:32:18 UTC 2627 followers, XXX engagements "$RARE FDA issues complete response letter to Ultragenyx for UX111 AAV gene therapy for Sanfilippo Syndrome Type A (MPS IIIA). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943770482744209508) 2025-07-11 20:32:51 UTC 2627 followers, XXX engagements "Health Canada has given the green light to Lilly's Omvoh (mirikizumab) for Crohn's Disease now available in a citrate-free formulation. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945106652040192316) 2025-07-15 13:02:18 UTC 2627 followers, XXX engagements "$OKYO OKYO Pharma announces promising Phase X trial data for Urcosimod in treating Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945476605067063570) 2025-07-16 13:32:22 UTC 2627 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $CRNX Crinetics will present Phase X Adrenal Hyperplasia Congenital Data for Atumelnant (MCR Antagonist - Small Molecule) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943629425394045011) 2025-07-11 11:12:20 UTC 2623 followers, XXX engagements "$CAPR Capricor Therapeutics updates on regulatory status of Deramiocel BLA for Duchenne Muscular Dystrophy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943619390425174429) 2025-07-11 10:32:28 UTC 2627 followers, 1377 engagements "Fast-track designation granted by FDA for DualityBio's Next-Generation HER3 ADC DB-1310. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947484861507506475) 2025-07-22 02:32:28 UTC 2624 followers, XXX engagements "$APTOF TSX:APS Aptose gets second advance from Hanmi Pharmaceutical for Tuspetinib development in AML triplet therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945235025827651995) 2025-07-15 21:32:25 UTC 2629 followers, XXX engagements "$AVXL Anavex Life Sciences reveals publication of Blarcamesine Phase IIb/III data in prestigious journal The Journal of Prevention of Alzheimer's Disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1879506854126158301) 2025-01-15 12:32:08 UTC 2628 followers, XXX engagements "Pharma/Biotech Highlights: $MNKD: MannKind expands patent portfolio with Clofazimine. $PHAT: FDA approves Phathom's Vonoprazan tablets. $BMY: EMA approves Bristol Myers Squibb's Opdivo. $DCPH: Positive Phase X results for Vimseltinib"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1719090631694324021) 2023-10-30 20:35:20 UTC 2623 followers, XXX engagements "$ONCY TSX:ONC Oncolytics Biotech showcases translated data showing Pelareorep's effectiveness in various tumor types. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945469347247616416) 2025-07-16 13:03:32 UTC 2627 followers, XXX engagements "$ELDN New findings from Eledon Pharmaceuticals' Phase 1b trial of Tegoprubart in kidney transplant patients will be shared at World Transplant Congress 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945944826559729743) 2025-07-17 20:32:55 UTC 2626 followers, XXX engagements "$BCDA Henry Ford Health begins enrolling patients for BioCardia's CardiAMP HF II study for Ischemic Heart Failure with Reduced Ejection Fraction. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945469355275505810) 2025-07-16 13:03:34 UTC 2627 followers, XXX engagements "Boehringer Ingelheim and LEO Pharma join forces to market and advance SPEVIGO (spesolimab) product. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721655726825569) 2025-07-14 11:32:28 UTC 2627 followers, XXX engagements "$OGEN Oragenics Inc. reveals drug manufacturing deal in the U.S. to aid ONP-002 clinical progress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945469369078956430) 2025-07-16 13:03:37 UTC 2627 followers, XXX engagements "$ALDX Aldeyra Therapeutics' NDA for Reproxalap in treating Dry Eye Disease accepted by FDA for review. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808936600514875) 2025-07-17 11:32:56 UTC 2626 followers, XXX engagements "$CNTB Simcere Pharmaceutical Connect Biopharma's Exclusive Licensee in China has submitted a New Drug Application for Rademikibart to treat Atopic Dermatitis in China. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1942947443987161452) 2025-07-09 14:02:23 UTC 2627 followers, XXX engagements "$MRK Health Canada approved KEYTRUDA to treat adult patients with FIGO 2014 Stage III-IVA cervical cancer alongside chemoradiotherapy (CRT). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947318700291535210) 2025-07-21 15:32:12 UTC 2626 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials of Obefazimod in treating moderate-severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947832210083746182) 2025-07-23 01:32:42 UTC 2625 followers, XXX engagements "$IVBIY In 2025 Innovent Biologics will present updated data on IBI363 (PD-1/IL-2-bias Bispecific Antibody Fusion Protein) in Phase X trials for advanced colorectal cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1929335353519071613) 2025-06-02 00:32:48 UTC 2623 followers, XXX engagements "$COCP Cocrystal Pharma will share Phase X study results for Norovirus Protease Inhibitor CDI-988 at 9th International Calicivirus Conference. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943287209421082871) 2025-07-10 12:32:29 UTC 2627 followers, XXX engagements "$BIVI BioVie showcased data at the 2nd World Conference on Aging highlighting potential age deceleration with Bezisterim treatment compared to placebo on XX different biological clocks. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360676050931980) 2025-07-24 12:32:38 UTC 2629 followers, XXX engagements "$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1942909752713134281) 2025-07-09 11:32:37 UTC 2629 followers, XXX engagements "$AQST Aquestive Therapeutics announces update on international expansion for Anaphylm (epinephrine) Sublingual Film. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945076465957265422) 2025-07-15 11:02:21 UTC 2623 followers, XXX engagements "Aicuris completed enrollment for pivotal trial of Pritelivir for refractory herpes simplex in immunocompromised patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948308001208852954) 2025-07-24 09:03:19 UTC 2630 followers, XXX engagements "$CSE:HLUNA CSE:HLUNB CSE:LUN Lundbeck expands dose finding for Lu AG09222 in migraine prevention after planned analysis in PROCEED trial includes intravenous administration. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1906799406143402348) 2025-03-31 20:02:59 UTC 2628 followers, XX engagements "$SXTP SXTPW XX Degrees Pharmaceuticals and Tulane University collaborate for research on Tafenoquine against Lyme and Bartonella bacteria. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823913403158638) 2025-07-17 12:32:27 UTC 2627 followers, XXX engagements "FDA fast tracks Addyi for postmenopausal women with low sexual desire enabling quicker access to treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360664092922144) 2025-07-24 12:32:35 UTC 2630 followers, XXX engagements "$CSE:BETR BetterLife Pharma issues scientific update on neuroplastogenic activity of BETR-001. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1927704549353210064) 2025-05-28 12:32:34 UTC 2628 followers, XXX engagements "$KRYS Jeune reports successful Phase X results for KB304 in treating moderate to severe dcollet wrinkles with noticeable aesthetic improvements. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360697089556878) 2025-07-24 12:32:43 UTC 2630 followers, XXX engagements "$LTRN Lantern Pharma gets EU patent for LP-284 strengthening global IP for AI-designed cancer treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273433890599143) 2025-07-21 12:32:19 UTC 2624 followers, XXX engagements "Novartis reaches agreement with pan-Canadian Pharmaceutical Alliance on Cosentyx for hidradenitis suppurativa (HS) treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943377786565226935) 2025-07-10 18:32:25 UTC 2627 followers, XXX engagements "$ARGX argenx progresses clinical development of ARGX-119 for Congenital Myasthenic Syndromes. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939557671314817282) 2025-06-30 05:32:38 UTC 2626 followers, XXX engagements "$PARIS:AB AB Science has been approved by multiple European countries to begin phase X study on masitinib for ALS. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948262436987187596) 2025-07-24 06:02:16 UTC 2630 followers, XXX engagements "$CGEN First patient dosed in COM701 Global Platform Trial for Platinum Sensitive Ovarian Cancer announced by Compugen. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258356433089004) 2025-07-21 11:32:25 UTC 2626 followers, XXX engagements "Ultomiris drug market projected to reach USD XXXXX billion by 2034 with a CAGR of 31.52%. Report covers analysis trends forecast segmentation growth rate and SWOT analysis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945340738432327841) 2025-07-16 04:32:29 UTC 2627 followers, XXX engagements "$AVTE FNA RSLS Halper Sadeh LLC is conducting a shareholder investigation on behalf of shareholders for FNA AVTE RSLS. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1903945429617958993) 2025-03-23 23:02:18 UTC 2625 followers, XXX engagements "Akeso starts Phase III trial of Ivonescimab for Pancreatic Cancer with first patient enrollment announced. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948194557948227758) 2025-07-24 01:32:32 UTC 2630 followers, XXX engagements "$IVBIY Phase X results of Innovent Biologics' IBI343 for advanced gastric/esophageal adenocarcinoma published in Nature Medicine. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945642697097908598) 2025-07-17 00:32:21 UTC 2625 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMAB I-Mab Biopharma will present Phase X Oncology Solid Tumor Unspecified Data for Givastomig (CLDN18.2 Inhibitor4-1BB Inhibitor - Bispecific Antibody) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940005523807772957) 2025-07-01 11:12:15 UTC 2627 followers, XXX engagements "Revalesio will discuss Phase X trial design and post hoc analysis of Phase X RESCUE trial of RNS60 in acute ischemic stroke at SNIS 22nd Annual Meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944782165864267972) 2025-07-14 15:32:55 UTC 2627 followers, XXX engagements "AGT announces promising results from AGT103-T HIV Functional Cure Program presented as late-breaker at International AIDS Society 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947681148131586117) 2025-07-22 15:32:26 UTC 2628 followers, XXX engagements "$ATRA Pierre Fabre Pharmaceuticals Inc. reveals FDA acceptance and priority review of Biologics License Application for Tabelecleucel for EBV+ PTLD treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948368151680614402) 2025-07-24 13:02:20 UTC 2630 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod an oral miR-124 enhancer for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947839761181512142) 2025-07-23 02:02:42 UTC 2628 followers, XXX engagements "$NBIX Neurocrine Biosciences reveals 1-year data demonstrating sustained effectiveness of CRENESSITY (crinecerfont) in adult patients at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944744285708206082) 2025-07-14 13:02:23 UTC 2624 followers, XXX engagements "Nxera Pharma to get $15M from Neurocrine Biosciences after dosing first patient in Phase X trial for NBI-1117568. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1929682542350975244) 2025-06-02 23:32:24 UTC 2625 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports encouraging Phase X results from ABTECT trials on Obefazimod for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947764286136455425) 2025-07-22 21:02:48 UTC 2630 followers, 1494 engagements "$SLS SELLAS achieves all main goals in Phase X trial of SLS009 for r/r AML and gets FDA approval for further study in first-line therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945091646187860348) 2025-07-15 12:02:41 UTC 2627 followers, XXX engagements "$ABOS Acumen Pharmaceuticals to share findings on cost savings from pTau217 screening in the Phase X ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at AAIC 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943287200348799391) 2025-07-10 12:32:27 UTC 2627 followers, XXX engagements "Nanoscope Therapeutics begins submitting BLA to FDA for MCO-010 the first gene-agnostic therapy for Retinitis Pigmentosa. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721677113585687) 2025-07-14 11:32:33 UTC 2627 followers, XXX engagements "$MIST Milestone Pharmaceuticals' response to the FDA CRL for CARDAMYST (etripamil) Nasal Spray has been accepted. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943619381604606386) 2025-07-11 10:32:25 UTC 2627 followers, XXX engagements "Windward Bio begins global Phase X asthma trial for WIN378 an anti-TSLP monoclonal antibody with potential as long-acting and best-in-disease treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948005787365986705) 2025-07-23 13:02:26 UTC 2626 followers, XXX engagements "Inotrem introduces revolutionary precision medicine approach for Nangibotide trials in septic shock treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948013356524445710) 2025-07-23 13:32:31 UTC 2626 followers, XXX engagements "$RDHL FDA provides positive feedback on RedHill's pathway for approval of RHB-204 for Crohn's Disease a groundbreaking treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947288537310933176) 2025-07-21 13:32:20 UTC 2625 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results in ABTECT trials for Obefazimod in moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947809437676408951) 2025-07-23 00:02:13 UTC 2625 followers, XXX engagements "$VSTM Fast track designation granted to Verastem Oncology for VS-7375 in treating KRAS G12D-mutated Pancreatic Cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948345506125750460) 2025-07-24 11:32:21 UTC 2630 followers, XXX engagements "$DARE Encouraging Phase X results demonstrate the potential of Ovaprene as a hormone-free contraceptive. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944736760153657462) 2025-07-14 12:32:29 UTC 2627 followers, XXX engagements "$ABBV AbbVie and Ichnos Glenmark Innovation (IGI) agree on exclusive global license for ISB 2001 a novel Trispecific Antibody targeting CD38 BCMA and CD3. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943287216513622157) 2025-07-10 12:32:31 UTC 2627 followers, XXX engagements "$PARIS:AB AB Science has received approval from several European countries to begin the confirmatory phase X study with masitinib in ALS. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948285139425054772) 2025-07-24 07:32:29 UTC 2630 followers, XXX engagements "$VIR First patient dosed in Phase X trial of EGFR-targeting VIR-5525 for solid tumors by Vir Biotechnology. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360703917875604) 2025-07-24 12:32:45 UTC 2630 followers, XXX engagements "$SXTP SXTPW ARAOKDA (tafenoquine) has an annual potential market size of $XXX million and cumulative sales of $XXX billion through patent expiration according to XX Degrees Pharmaceuticals. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945084019005325710) 2025-07-15 11:32:22 UTC 2627 followers, XXX engagements "$BRCTF Lecanemab's drug discovery research receives 9th Bioindustry Award from Japan Bioindustry Association. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945393526902284520) 2025-07-16 08:02:15 UTC 2626 followers, XXX engagements "Hengrui Pharma and Kailera Therapeutics announce successful results from Phase X obesity trial in China for HRS9531 a dual GLP-1/GIP Receptor Agonist. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945091652286341165) 2025-07-15 12:02:42 UTC 2627 followers, XXX engagements "$IDYA IDEAYA Biosciences to present Phase X Clinical Trial of Neoadjuvant Darovasertib at ESMO 2025 for Primary Uveal Melanoma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948375737167409474) 2025-07-24 13:32:29 UTC 2630 followers, XXX engagements "$NBIX Neurocrine Biosciences shares new data from KINECT-HD Study showing INGREZZA reduces disease burden in Huntington's Chorea. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1938583656324534453) 2025-06-27 13:02:15 UTC 2624 followers, XXX engagements "First patient dosed in Phase 1b/2a trial of Procizumab a monoclonal antibody targeting shock's biological driver. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947960470293684531) 2025-07-23 10:02:22 UTC 2626 followers, XXX engagements "$CSE:HLUNA CSE:HLUNB CSE:LUN Lundbeck expands Lu AG09222 dose finding to intravenous administration for migraine prevention after PROCEED trial interim analysis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1906822100117307414) 2025-03-31 21:33:10 UTC 2628 followers, XXX engagements "$BIIB STOK Biogen and Stoke Therapeutics will share data on Zorevunersen for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943279659543859447) 2025-07-10 12:02:29 UTC 2622 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT trials using Obefazimod for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947794374701793596) 2025-07-22 23:02:21 UTC 2624 followers, XXX engagements "$AZN Baxdrostat successfully met all main and additional goals in Phase III trial for uncontrolled or treatment resistant hypertension in patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721669312151680) 2025-07-14 11:32:31 UTC 2627 followers, XXX engagements "$SXTP SXTPW XX Degrees Pharmaceuticals plans to request MUMS designation from FDA in 2025 for Tafenoquine to treat Acute Canine Babesiosis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944857532859867430) 2025-07-14 20:32:24 UTC 2627 followers, XXX engagements "$HALO DARZALEX Faspro approved by EU Commission for adult patients with Smouldering Multiple Myeloma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948051067931177115) 2025-07-23 16:02:22 UTC 2626 followers, XXX engagements "DCA opens today to enhance Asia's data center network. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947243223421988895) 2025-07-21 10:32:17 UTC 2626 followers, XXX engagements "$KMSTF NLSP NLS Pharmaceutics reports progress in iTOL-102 program as BIRD Foundation approves payment to Kadimastem and iTolerance for Type X Diabetes therapy development. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808960352903268) 2025-07-17 11:33:02 UTC 2626 followers, XXX engagements "miraDry receives EU MDR certification and expands indications for reducing sweat odor and hair in Europe. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943362777466442088) 2025-07-10 17:32:46 UTC 2627 followers, XXX engagements "$HOTH Hoth Therapeutics partners with VA for GDNF research targeting obesity and fatty liver. Study underway comparing GDNF to Semaglutide. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635807444959541) 2025-07-22 12:32:16 UTC 2630 followers, XXX engagements "$ONCY TSX:ONC Key Opinion Leader Event sheds light on Pelareorep's promising data in pancreatic and gastrointestinal fields highlighting its future potential. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948020937611464916) 2025-07-23 14:02:38 UTC 2629 followers, XXX engagements "$PMN U.S. FDA grants ProMIS Neurosciences Fast Track Designation for PMN310 in Alzheimer's Disease treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273427477549322) 2025-07-21 12:32:18 UTC 2626 followers, XXX engagements "$CADL Candel Therapeutics obtains EMA Orphan Designation for CAN-2409 for Pancreatic Cancer treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360670141141441) 2025-07-24 12:32:37 UTC 2630 followers, XXX engagements "Reunion Neuroscience reports publication of RE104 Phase X Data in The Journal of Clinical Psychopharmacology. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620693241434545) 2025-07-22 11:32:12 UTC 2626 followers, XXX engagements "First patient enrolled in Phase 2a trial of 4P004 by Moving Biotech for knee osteoarthritis. 4P004 is a potential first-in-class GLP-1 therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945348235113193734) 2025-07-16 05:02:16 UTC 2627 followers, XXX engagements "$MRK FDA gives the go-ahead for Merck Animal Health's BRAVECTO QUANTUM (Fluralaner for Extended-Release Injectable Suspension). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943415516376531332) 2025-07-10 21:02:20 UTC 2627 followers, XXX engagements "Genascence receives FDA approval for GNSC-001 as a Regenerative Medicine Advanced Therapy for Knee Osteoarthritis (OA) in the U.S. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453994773745785) 2025-07-16 12:02:31 UTC 2627 followers, XXX engagements "$RCKT RCKT stock plunges due to FDA Clinical Hold on RP-A501 trial sparking Class Action by Hagens Berman. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945929703132729508) 2025-07-17 19:32:49 UTC 2626 followers, XXX engagements "$BCDA BioCardia wants to meet with Japan PMDA to talk about getting approval for CardiAMP Cell Therapy in Ischemic Heart Failure. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948375730641043774) 2025-07-24 13:32:27 UTC 2630 followers, XXX engagements "Oak Hill Bio has published results of Rugonersen Phase X study in Nature Medicine. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943596682194903077) 2025-07-11 09:02:13 UTC 2627 followers, XXX engagements "$GLUE Phase X study of MRT-8102 a NEK7-Directed Molecular Glue Degrader for treating inflammatory diseases begins with dosing of first subjects by Monte Rosa Therapeutics. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258369326334140) 2025-07-21 11:32:28 UTC 2624 followers, XXX engagements "$CASI CASI Pharmaceuticals names David Cory as CEO to lead U.S. company focusing on CID-103 clinical development a promising Anti-CD38 program. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947394246950195463) 2025-07-21 20:32:23 UTC 2625 followers, XXX engagements "$AGEN GSK GSK's SHINGRIX now approved by US FDA in prefilled syringe. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808945345622404) 2025-07-17 11:32:58 UTC 2626 followers, XXX engagements "$ASND Updated Phase X results show continued positive response to TransCon PTH treatment for adults with hypoparathyroidism with benefits in biochemistries kidney function and quality of life. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944857538438303976) 2025-07-14 20:32:25 UTC 2626 followers, XXX engagements "$RARE Health Canada approves Evkeeza (evinacumab) for children as young as X months with Homozygous Familial Hypercholesterolemia (HoFH). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944736741283533085) 2025-07-14 12:32:25 UTC 2627 followers, XXX engagements "$RVMD Revolution Medicines announces publication in Science on Zoldonrasib a selective inhibitor for RAS(ON) G12D. Discovery and development detailed in peer-reviewed paper. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948473855816659447) 2025-07-24 20:02:22 UTC 2630 followers, XXX engagements "$ALNY OXLUMO (lumasiran injection) is now reimbursed in Canada for treating Primary Hyperoxaluria Type X (PH1) in pediatric and adult patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940456256696996052) 2025-07-02 17:03:18 UTC 2627 followers, XXX engagements "$PHGE BiomX starts Phase 2b trial for BX004 in Cystic Fibrosis patients first patient dosed successfully. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944744294470078780) 2025-07-14 13:02:26 UTC 2626 followers, XXX engagements "KERENDIA (finerenone) approved by U.S. FDA to treat heart failure patients with LVEF XX% after Priority Review. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944646135655834073) 2025-07-14 06:32:23 UTC 2627 followers, XXX engagements "$MDGL Madrigal Pharmaceuticals has been granted a new U.S. patent by the Patent and Trademark Office for Rezdiffra (Resmetirom). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945461508689064259) 2025-07-16 12:32:23 UTC 2627 followers, XXX engagements "$ZVRA MIPLYFFA (arimoclomol) by Zevra Therapeutics will be highlighted in presentations at the National Niemann Pick Disease Foundation Conference. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943634424681431183) 2025-07-11 11:32:12 UTC 2627 followers, XXX engagements "Government endorses SNB-101 as promising Small Cell Lung Cancer therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945461515370598521) 2025-07-16 12:32:24 UTC 2627 followers, XXX engagements "$RARE Ultragenyx gets Breakthrough Therapy status for GTX-102 in Angelman Syndrome. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1938576148390400183) 2025-06-27 12:32:25 UTC 2622 followers, XXX engagements "Alzheon will share details on Valiltramiprosate/ALZ-801 at Alzheimer's conference in Toronto on July XX 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945068916998594687) 2025-07-15 10:32:22 UTC 2626 followers, XXX engagements "$RVMD FDA grants Breakthrough Therapy Designation to Revolution Medicines' Elironrasib. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998237060964513) 2025-07-23 12:32:26 UTC 2630 followers, XXX engagements "Diakonos Oncology reports first patient dosed in Phase X trial of DOC1021 for Glioblastoma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635820032032822) 2025-07-22 12:32:19 UTC 2627 followers, XXX engagements "ReAlta Life Sciences releases data showing RLS-0071 decreases brain inflammation in preclinical hypoxic ischemic encephalopathy model. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635814181310641) 2025-07-22 12:32:18 UTC 2626 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod in treating Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947786816930910555) 2025-07-22 22:32:19 UTC 2624 followers, XXX engagements "$KROS Keros Therapeutics initiates Phase X RENEW Clinical Trial of Elritercept with first patient dosing announced. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823922462900330) 2025-07-17 12:32:29 UTC 2627 followers, XXX engagements "$KZR FDA lifted partial clinical hold on PORTOLA Phase 2a Trial of Zetomipzomib for Autoimmune Hepatitis by Kezar Life Sciences. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945227456832737770) 2025-07-15 21:02:20 UTC 2627 followers, XXX engagements "Canada approves Blenrep combos for relapsed/refractory multiple myeloma treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947983118478278810) 2025-07-23 11:32:21 UTC 2630 followers, XXX engagements "First patient dosed by OncoC4 with potential best-in-class PD-1/VEGF bispecific antibody AI-081 in Phase X of BIPAVE-001 trial for solid tumors in US. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620709531889789) 2025-07-22 11:32:16 UTC 2626 followers, XXX engagements "$CORT New Drug Application submitted by Corcept for Relacorilant intended for patients with Platinum-Resistant Ovarian Cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944736748279627979) 2025-07-14 12:32:26 UTC 2629 followers, XXX engagements "$QDEL QuidelOrtho and BHLMANN Laboratories AG introduce FCAL Turbo and FPELA Turbo assays on Vitros Systems as a MicroTip Partnership Assay. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721663209406548) 2025-07-14 11:32:30 UTC 2623 followers, XXX engagements "Apnimed announces positive results from Phase X trial of AD109 showing potential as first oral pill for obstructive sleep apnea. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947968042648154326) 2025-07-23 10:32:27 UTC 2628 followers, XXX engagements "$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946178701269611001) 2025-07-18 12:02:15 UTC 2626 followers, XXX engagements "First patient dosed in Phase X trial of MOMA-341 a potent Werner Helicase Inhibitor by MOMA Therapeutics. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823939143602495) 2025-07-17 12:32:33 UTC 2626 followers, XXX engagements "$CSE:RVV RVVTF Revive Therapeutics updates focus on R&D activities for Bucillamine in treating infectious diseases and medical countermeasures. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1886535776437199278) 2025-02-03 22:02:33 UTC 2628 followers, XXX engagements "Ammonium Chloride Market projected to reach $XXXX billion by 2034. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948043747507544398) 2025-07-23 15:33:16 UTC 2627 followers, XXX engagements "$OTLC SAPU Bioscience highlights study linking TGFB2 to survival in younger pancreatic cancer patients in peer-reviewed publication. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946020309389463688) 2025-07-18 01:32:51 UTC 2626 followers, XXX engagements "$SILO Silo Pharma finishes dosing in safety study for PTSD drug SPC-15. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945469361902555147) 2025-07-16 13:03:35 UTC 2627 followers, XXX engagements "$LSTA Lisata Therapeutics obtains new composition of matter patent for Certepetide strengthening its intellectual property portfolio. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945099132433260882) 2025-07-15 12:32:26 UTC 2627 followers, XXX engagements "$SLDB FDA grants Fast Track Designation to Solid Biosciences for SGT-501 a first-of-its-kind gene therapy for CPVT. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998243591500270) 2025-07-23 12:32:27 UTC 2629 followers, XXX engagements "$KRRO KRRO-110 from Korro granted Orphan Drug Designation by European Medicines Agency. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273440945451053) 2025-07-21 12:32:21 UTC 2625 followers, XXX engagements "$RGNX REGENXBIO reports preclinical data showing benefits of new Microdystrophin in RGX-202 for Duchenne Muscular Dystrophy gene therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943340016656380261) 2025-07-10 16:02:20 UTC 2627 followers, XXX engagements "Cloudbreak Pharma Inc. reports encouraging Phase X findings for CBT-004 in patients with Vascularized Pinguecula. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947092204708855966) 2025-07-21 00:32:11 UTC 2624 followers, XXX engagements "$IDYA IDEAYA and Hengrui reveal IDE849 for IASLC 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947711300655845785) 2025-07-22 17:32:15 UTC 2630 followers, XXX engagements "$TLSA Tiziana Life Sciences reveals immune system analysis of nasal Foralumab in patients with moderate Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258337080566036) 2025-07-21 11:32:20 UTC 2625 followers, XXX engagements "Revalesio has published results of RESCUE Phase X Trial evaluating RNS60 as additional therapy for Acute Ischemic Stroke in Stroke journal. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273415712534923) 2025-07-21 12:32:15 UTC 2626 followers, XXX engagements "Imugene reports high response rates in Phase 1b trial of Azer-cel CAR T for 3L+ DLBCL. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944623452507512914) 2025-07-14 05:02:15 UTC 2627 followers, XXX engagements "$PFE ViiV Healthcare found that XX% of HIV patients new to treatment opt for long-acting injectables Vocabria + Rekambys over daily pills after fast viral suppression. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944759370178511229) 2025-07-14 14:02:20 UTC 2627 followers, XXX engagements "$IMAB I-Mab acquires Bridge Health to enhance Givastomig IP portfolio. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808968561160397) 2025-07-17 11:33:04 UTC 2626 followers, XXX engagements "$SWTX European Commission conditionally approves EZMEKLY (mirdametinib) for treating NF1-PN in adult and pediatric patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946239709015085116) 2025-07-18 16:04:40 UTC 2628 followers, 1013 engagements "$CELC First patient in Phase X VIKTORIA-2 trial of Gedatolisib for HR+/HER2Advanced Breast Cancer dosed by Celcuity as first-line treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948481423783936447) 2025-07-24 20:32:27 UTC 2630 followers, XXX engagements "Polivy (polatuzumab vedotin) by Roche Canada is now publicly reimbursed in Quebec for first-line treatment of large B-cell lymphoma in adults. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947650899213750497) 2025-07-22 13:32:14 UTC 2627 followers, XXX engagements "$ACET Adicet Bio dosed the first Systemic Sclerosis patient in Phase X trial of ADI-001 for Autoimmune Diseases. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948338030974226558) 2025-07-24 11:02:39 UTC 2630 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMAB I-Mab Biopharma will present Phase X Gastrointestinal Cancer Data for Givastomig (CLDN18.2 Inhibitor4-1BB Inhibitor - Bispecific Antibody) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940005524449419621) 2025-07-01 11:12:15 UTC 2627 followers, XXX engagements "$CYBN Cybin approved by UK MHRA for EMBRACE study on CYB003 in treating Major Depressive Disorder. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808952933118256) 2025-07-17 11:33:00 UTC 2626 followers, XXX engagements "$AUTL European Marketing Authorization approved for Autolus Therapeutics' CAR T therapy AUCATZYL for adults (26+) with relapsed or refractory B-ALL. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258343313314024) 2025-07-21 11:32:22 UTC 2626 followers, XXX engagements "ANZUPGO Cream is the first FDA-approved treatment for moderate-to-severe Chronic Hand Eczema in adults. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948126569308000548) 2025-07-23 21:02:23 UTC 2629 followers, XXX engagements "$ATRA Atara Biotherapeutics shares regulatory and business updates for Tab-cel also known as Tabelecleucel. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944736754214547656) 2025-07-14 12:32:28 UTC 2626 followers, XXX engagements "$KALV KalVista Pharmaceuticals has received UK MHRA approval for EKTERLY (sebetralstat) the first and only oral on-demand treatment for Hereditary Angioedema. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945219941680210053) 2025-07-15 20:32:29 UTC 2627 followers, XXX engagements "$REPL FDA issues Complete Response Letter to Replimune for RP1 Biologics License Application for Advanced Melanoma treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620700803792908) 2025-07-22 11:32:14 UTC 2626 followers, 1181 engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-week induction trials of Obefazimod in treating moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947816984931868798) 2025-07-23 00:32:12 UTC 2624 followers, XXX engagements "$PTGX Protagonist submits NDA for first Icotrokinra FDA approval aiming to revolutionize plaque psoriasis treatment for adults and adolescents. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273421307691354) 2025-07-21 12:32:16 UTC 2627 followers, XXX engagements "FDA grants Orphan Drug Designation to ImCheck's ICT01 for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946141009383215200) 2025-07-18 09:32:28 UTC 2626 followers, XXX engagements "$ANNX Enrollment in pivotal Phase X ARCHER II trial of Vonaprument (formerly ANX007) for Dry AMD with Geographic Atrophy completed by Annexon. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948338024838013218) 2025-07-24 11:02:38 UTC 2630 followers, XXX engagements "$CVRX CVRx reports positive update on Barostim outpatient payment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453987358195724) 2025-07-16 12:02:30 UTC 2626 followers, XXX engagements "$IONS New study in JACI In Practice shows how donidalorsen benefits HAE patients who switched from other treatments in Phase X OASISplus data. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258350670127142) 2025-07-21 11:32:23 UTC 2626 followers, XXX engagements "$TNXP Tonix Pharmaceuticals will present new data on Mpox and smallpox vaccine TNX-801 at Vaccine Congress 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272668029219032) 2025-07-10 11:34:42 UTC 2629 followers, 3262 engagements "$RHHBY Genentech updates on Astegolimab in COPD. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947167696304718306) 2025-07-21 05:32:10 UTC 2627 followers, XXX engagements "$BIIB STOK Stoke Therapeutics and Biogen will present data on Zorevunersen an investigational medicine for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272651973390769) 2025-07-10 11:34:39 UTC 2622 followers, XXX engagements "$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823930666934771) 2025-07-17 12:32:31 UTC 2627 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials for ABTECT 8-week induction using Obefazimod for moderate to severe ulcerative colitis a first-of-its-kind oral miR-124 enhancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947771757282398451) 2025-07-22 21:32:29 UTC 2630 followers, XXX engagements "$AAPG China NMPA approves Ascentage Pharma's Lisaftoclax a novel Bcl-2 inhibitor marking a new era in CLL/SLL treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943310378060099717) 2025-07-10 14:04:33 UTC 2627 followers, XXX engagements "$CGTX Cognition Therapeutics releases study examining how Zervimesine shields neurons and synapses in Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947265857270534315) 2025-07-21 12:02:13 UTC 2626 followers, XXX engagements "$IMAB I-Mab shows promising data on Givastomig in combo with immunotherapy in 1L gastric cancer patients at ESMO GI 2025. Phase 1b results are positive. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940433407454109867) 2025-07-02 15:32:30 UTC 2626 followers, XXX engagements "$IVBIY Innovent initiates Phase X trial for IBI354 a new HER2 ADC in platinum-resistant ovarian cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1903968121867890788) 2025-03-24 00:32:28 UTC 2627 followers, XXX engagements "$IRON Disc Medicine confirms plan to submit NDA for Bitopertin in EPP in October 2025 after positive pre-NDA meeting announcement. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273409840488919) 2025-07-21 12:32:14 UTC 2627 followers, XXX engagements "$IMAB I-Mab releases Givastomig Monotherapy Data in Clinical Cancer Research. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939784175571345836) 2025-06-30 20:32:41 UTC 2628 followers, XXX engagements "$ATYR aTyr Pharma reports completion of Phase X EFZO-FIT study of Efzofitimod in patients with pulmonary sarcoidosis. Last patient visit announced. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947628237364072806) 2025-07-22 12:02:11 UTC 2630 followers, XXX engagements "tr Chitosan patents new USP inhalant product. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945197267528638812) 2025-07-15 19:02:23 UTC 2627 followers, XXX engagements "Eisai to share four-year efficacy and safety results for continuous treatment with lecanemab at Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947447166949331097) 2025-07-22 00:02:41 UTC 2624 followers, XXX engagements "$BMY Bristol Myers Squibb reports Phase X INDEPENDENCE Trial topline findings for Reblozyl in adults with Myelofibrosis-Associated Anemia. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946163606707667256) 2025-07-18 11:02:16 UTC 2623 followers, XXX engagements "$RHHBY Genentech updates on FDA application for Columvi combo for patients with relapsed or refractory Diffuse Large B-cell Lymphoma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946239716480963035) 2025-07-18 16:04:42 UTC 2627 followers, 1684 engagements "$RPTX Repare Therapeutics and Debiopharm have signed an exclusive global licensing deal for Lunresertib. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945219932716970213) 2025-07-15 20:32:27 UTC 2627 followers, XXX engagements "$GILD Gilead shares new research on lenacapavir's effectiveness for HIV prevention at IAS 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944759376243544306) 2025-07-14 14:02:21 UTC 2623 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT 8-Week trial on Obefazimod for Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947779263241101458) 2025-07-22 22:02:19 UTC 2630 followers, XXX engagements "$GMAB Genmab reports DARZALEX (daratumumab) net sales for Q2 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945431290842664995) 2025-07-16 10:32:18 UTC 2627 followers, XXX engagements "Eisai will share four-year efficacy and safety data on continuous treatment with Lecanemab at the Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947567825000009931) 2025-07-22 08:02:08 UTC 2626 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947847592425230474) 2025-07-23 02:33:49 UTC 2624 followers, XXX engagements "Long-acting fully human anti-TSLP antibody HBM9378/WIN378 enters global Phase X POLARIS trial for asthma treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948020944741818570) 2025-07-23 14:02:40 UTC 2626 followers, XXX engagements "$ADAG Adagene provides regulatory update on clinical plan for Muzastotug in microsatellite stable colorectal cancer after successful FDA meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945076458277495035) 2025-07-15 11:02:20 UTC 2623 followers, XXX engagements "Italfarmaco reveals new cardiac findings on Givinostat at 16th EPNS Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943589162315366548) 2025-07-11 08:32:21 UTC 2627 followers, XXX engagements "$HIMS Securities class actions initiated against Hims & Hers Health Inc. (HIMS) for alleged deceptive marketing of Wegovy. Investors with losses urged to contact Hagens Berman. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945929694886662219) 2025-07-17 19:32:47 UTC 2623 followers, XXX engagements "$UNCY Unicycive Therapeutics releases Oxylanthanum Carbonate trial results in Clinical Journal of the American Society of Nephrology. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360691016241171) 2025-07-24 12:32:42 UTC 2630 followers, XXX engagements "$OKYO OKYO Pharma secures $1.9M in non-dilutive funding to speed up Urcosimod development for Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945831540661047685) 2025-07-17 13:02:45 UTC 2626 followers, XXX engagements "ImCheck's ICT01 has received Orphan Drug Designation from the EMA for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258362594537729) 2025-07-21 11:32:26 UTC 2626 followers, XXX engagements "$ALMS Alumis finishes enrolling patients in global LUMUS Phase 2b trial of ESK-001 an advanced oral TYK2 inhibitor for treating Systemic Lupus Erythematosus. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948345499792322822) 2025-07-24 11:32:20 UTC 2630 followers, XXX engagements "$OTLC Oncotelic Therapeutics points to study linking TGFB2 to survival in younger pancreatic cancer patients in new publication. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945869179351171556) 2025-07-17 15:32:19 UTC 2626 followers, XXX engagements "$RCKT Rocket Pharmaceuticals gets FDA RMAT Designation for RP-A601 gene therapy for PKP2-Arrhythmogenic Cardiomyopathy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808976576409769) 2025-07-17 11:33:06 UTC 2626 followers, XXX engagements "AusperBio has obtained China CDE approval to progress AHB-137 to Phase III clinical trial for Chronic Hepatitis B treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947386667628957812) 2025-07-21 20:02:16 UTC 2624 followers, XXX engagements "$ZVRA Zevra Therapeutics reveals data from open label extension proving MIPLYFFA's long-term effectiveness in treating NPC published in Journal of Molecular Genetics and Metabolism. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453971688288631) 2025-07-16 12:02:26 UTC 2627 followers, XXX engagements "$ATRA Pierre Fabre Pharmaceuticals Inc. moves Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics Inc. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945099140289191963) 2025-07-15 12:32:27 UTC 2627 followers, XXX engagements "ORYZON is enhancing its patent portfolio for Vafidemstat. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944729156450918401) 2025-07-14 12:02:16 UTC 2627 followers, XXX engagements "$LTRN Lantern Pharma announces full response in highly treated lymphoma patient with LP-284 in Phase X trial. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947990646461231375) 2025-07-23 12:02:16 UTC 2626 followers, XXX engagements "Eolas Therapeutics now has complete control over the development of AZD4041. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943287191750508935) 2025-07-10 12:32:25 UTC 2627 followers, XXX engagements "$KAPA Safety results from Phase X trial of ENV-105 in advanced prostate cancer by Kairos Pharma show positive outcomes. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945099147444675035) 2025-07-15 12:32:29 UTC 2627 followers, XXX engagements "$TAK TYO:4502 Takeda reports positive outcomes from two Phase X trials of Oveporexton (TAK-861) in Type X Narcolepsy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944661207551811897) 2025-07-14 07:32:16 UTC 2627 followers, XXX engagements "Spherix Global Insights reports GSK's Linerixibat set to help with unmet needs in treating pruritus linked to Primary Biliary Cholangitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945899455003455996) 2025-07-17 17:32:37 UTC 2623 followers, XXX engagements "4TEEN4 reveals in European Journal of Heart Failure successful reversal of shock in first human trials using Procizumab in three compassionate cases. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945053818754097513) 2025-07-15 09:32:22 UTC 2627 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports promising Phase X findings on ABTECT 8-Week Induction Trials for Obefazimod an oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947757076627001502) 2025-07-22 20:34:09 UTC 2624 followers, 1002 engagements "$AZN TAGRISSO combined with chemotherapy showed significant and meaningful enhancement in overall survival for EGFR-mutated advanced lung cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258330034139213) 2025-07-21 11:32:18 UTC 2626 followers, XXX engagements "$ENSC Ensysce Biosciences starts Phase X trial for PF614 a new opioid for pain relief with abuse deterrent properties. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945461522312069208) 2025-07-16 12:32:26 UTC 2627 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-Week Induction Trials of Obefazimod in patients with moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947801890529677601) 2025-07-22 23:32:13 UTC 2624 followers, XXX engagements "$ENVB Enveric Biosciences gets second U.S. patent allowance for non-hallucinogenic mescaline derivatives in EVM401 Series. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998249929072722) 2025-07-23 12:32:29 UTC 2628 followers, XXX engagements "$PARIS:COX PARIS:FR Nicox and Kowa ink deal worth XXXXX million granting exclusive rights to Glaucoma Treatment NCX XXX in U.S. and unlicensed territories. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945718204485284319) 2025-07-17 05:32:24 UTC 2626 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947824536189342085) 2025-07-23 01:02:12 UTC 2625 followers, XXX engagements "GenSight Biologics reports study results on factors predicting final visual outcome in patients who received LUMEVOQ gene therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945831532326990138) 2025-07-17 13:02:43 UTC 2627 followers, XXX engagements "Akeso has enrolled the first patient in Phase III trial (AK112-312/HARMONi-GI6) for Ivonescimab in advanced metastatic colorectal cancer treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945302953881165975) 2025-07-16 02:02:20 UTC 2626 followers, XXX engagements "$RYTM Rhythm Pharmaceuticals shares findings on MC4R agonists Setmelanotide and Bivamelagon at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944155366343979337) 2025-07-12 22:02:14 UTC 2627 followers, XXX engagements "$ENVB Enveric Biosciences' top drug candidate EB-003 shows promise in preclinical PTSD model with positive effects. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945114198767514092) 2025-07-15 13:32:18 UTC 2627 followers, 2751 engagements "$CYTK Cytokinetics reveals five presentations on Aficamten at ESC Congress 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272645786767545) 2025-07-10 11:34:37 UTC 2624 followers, XXX engagements "$RCKT FDA Clinical Hold on RP-A501 Trial causes Rocket Pharmaceuticals (RCKT) stock to plummet and leads to Class Action lawsuit by Hagens Berman. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948149744532144136) 2025-07-23 22:34:28 UTC 2630 followers, XXX engagements "Kelun-Biotech's partner Windward Bio starts global Phase X trial for SKB378/WIN378 in asthma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948013362295763063) 2025-07-23 13:32:32 UTC 2630 followers, XXX engagements "$BRCTF New data on Lecanemab's effectiveness and safety over four years will be shared at AAIC 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947545231177748678) 2025-07-22 06:32:21 UTC 2626 followers, XXX engagements "$ORKA Oruka Therapeutics gets IND clearance for EVERLAST-A Phase 2a trial of ORKA-001 in Psoriasis. Phase X data to be detailed at EADV in September. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258375143817664) 2025-07-21 11:32:29 UTC 2627 followers, XXX engagements "$OCGN First patient dosed in Phase 2/3 GARDian3 trial for OCU410ST a gene therapy candidate for Stargardt Disease announced by Ocugen Inc. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946171170883252410) 2025-07-18 11:32:19 UTC 2626 followers, 1236 engagements "Alkeus Pharmaceuticals to present Gildeuretinol data at ASRS 43rd Annual Meeting on July 29-August X. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998230656303521) 2025-07-23 12:32:24 UTC 2626 followers, XXX engagements "$JNJ Johnson & Johnson aims for US FDA approval of icotrokinra to change treatment for adults and teens with plaque psoriasis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947280960367804609) 2025-07-21 13:02:14 UTC 2624 followers, XXX engagements "Hillhurst Biopharmaceuticals administers first dose in Phase 2a trial for HBI-002 a new treatment for Sickle Cell Disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948111515078504861) 2025-07-23 20:02:34 UTC 2630 followers, XXX engagements "$CMND CSE:CMND Clearmind Medicine finishes starting trial at top Israeli site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948005780361495026) 2025-07-23 13:02:24 UTC 2626 followers, XXX engagements "$CELC Celcuity announces new patent for Gedatolisib extending exclusivity until 2042. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944721639213773222) 2025-07-14 11:32:24 UTC 2625 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@OzmosiHealth Ozmosi
Ozmosi posts on X about more info, $pph, $xph, $ibb the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +95%
- X Month XXXXXXX +42%
- X Months XXXXXXX +12%
- X Year XXXXXXXXX +86%
Mentions: XX #
- X Week XXX -XX%
- X Month XXX -XXXX%
- X Months XXXXX +27%
- X Year XXXXX +68%
Followers: XXXXX #
- X Week XXXXX +9.10%
- X Month XXXXX +11%
- X Months XXXXX +24%
- X Year XXXXX +42%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXX% countries XXX% cryptocurrencies XXXX% finance XXXX% currencies XXXX% automotive brands XXXX% travel destinations XXXX% technology brands XXXX%
Social topic influence more info #204, $pph #1, $xph #1, $ibb #1, $xbi #3, $abvx 1.6%, canada 0.74%, $imab 0.61%, alzheimers 0.61%, $atra #1
Top accounts mentioned or mentioned by @marketwirenews @salmanfirat2 @john06746191 @stewdomer @dwill3000 @chrismangum14 @nicolem52807658 @towiu2 @mitchellreed09
Top assets mentioned Bitcoin Incognito (XBI) SuperRare (RARE) Bristol-Myers Squibb Co (BMY) Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Merck & Co., Inc. (MRK) Krystal Biotech, Inc. Common Stock (KRYS) Neurocrine Biosciences, Inc. (NBIX) IDEAYA Biosciences, Inc. Common Stock (IDYA) Biogen Inc (BIIB) AstraZeneca PLC (AZN) Revolution Medicines, Inc. Common Stock (RVMD) Crinetics Pharmaceuticals, Inc. (CRNX) Novartis AG (NVS) Mist (MIST) AbbVie Inc (ABBV) Vir Biotechnology, Inc. Common Stock (VIR) Halozyme Therapeutics, Inc. (HALO)
Top Social Posts #
Top posts by engagements in the last XX hours
"$RCUS Arcus Biosciences' Quemliclustat granted Orphan Drug Designation for Pancreatic Cancer. More Info: $XBI $IBB $XPH $PPH"
@OzmosiHealth on X 2025-07-10 13:02:22 UTC 2627 followers, XXX engagements
"HanchorBio moves forward with global impact of HCB101 immunotherapy. Listed on TPEx. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:32:24 UTC 2627 followers, XXX engagements
"365mc and Raziel Therapeutics partner to expedite RZL-012 development in South Korea. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 12:32:24 UTC 2627 followers, XXX engagements
"$CRDL TSX:CRDL Cardiol Therapeutics locks database for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:11 UTC 2626 followers, XXX engagements
"$RHHBY Roche's latest announcement provides an update on the use of astegolimab in treating chronic obstructive pulmonary disease in accordance with Art. XX LR. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 06:02:38 UTC 2627 followers, XXX engagements
"$NRSN Join Aaron Lazar and NeuroSense CEO Alon Ben-Noon in a live podcast discussing ALS science PrimeC's strategies and community impact. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 13:02:11 UTC 2628 followers, XXX engagements
"$NGENF TSXV:NGEN NervGen Pharma announces positive results in Phase 1b/2a trial for NVG-291 in Spinal Cord Injury. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-02 11:33:13 UTC 2623 followers, 1038 engagements
"$WALD Waldencast buys Novaestiq Corp. and U.S. rights for Saypha injectable hyaluronic acid gel line under Obagi Medical brand. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 11:02:26 UTC 2626 followers, XXX engagements
"$BMY Bristol Myers Squibb's sNDA for Sotyktu (deucravacitinib) in treating active Psoriatic Arthritis accepted for review in four regions worldwide. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:02:05 UTC 2628 followers, XXX engagements
"$ATRA Atara Biotherapeutics reports FDA acceptance and priority review of Biologics License Application for Tab-cel to treat EBV+ post-transplant lymphoproliferative disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:40 UTC 2630 followers, XXX engagements
"WHO adds ArkBio's Ziresovir to list of priority drugs for pediatric RSV. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 01:32:22 UTC 2627 followers, XXX engagements
"Pharma/Biotech Highlights: $MRNS: Marinus Pharma reports Q4 2023 earnings. $RYTM: Rhythm Pharma screens for obesity treatment. $NWPHF: Evenamide shows promise in treating TRS. $RARE: Ultragenyx's Evkeeza recommended in UK" @OzmosiHealth on X 2024-01-04 21:25:14 UTC 2627 followers, XXX engagements
"Aviva Biopharm Inc. presents new pre-clinical data on d3-T a groundbreaking testosterone therapy for women at ENDO 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 13:32:18 UTC 2627 followers, XXX engagements
"$RARE FDA issues complete response letter to Ultragenyx for UX111 AAV gene therapy for Sanfilippo Syndrome Type A (MPS IIIA). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-11 20:32:51 UTC 2627 followers, XXX engagements
"Health Canada has given the green light to Lilly's Omvoh (mirikizumab) for Crohn's Disease now available in a citrate-free formulation. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 13:02:18 UTC 2627 followers, XXX engagements
"$OKYO OKYO Pharma announces promising Phase X trial data for Urcosimod in treating Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:32:22 UTC 2627 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $CRNX Crinetics will present Phase X Adrenal Hyperplasia Congenital Data for Atumelnant (MCR Antagonist - Small Molecule) tomorrow 👀" @OzmosiHealth on X 2025-07-11 11:12:20 UTC 2623 followers, XXX engagements
"$CAPR Capricor Therapeutics updates on regulatory status of Deramiocel BLA for Duchenne Muscular Dystrophy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-11 10:32:28 UTC 2627 followers, 1377 engagements
"Fast-track designation granted by FDA for DualityBio's Next-Generation HER3 ADC DB-1310. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 02:32:28 UTC 2624 followers, XXX engagements
"$APTOF TSX:APS Aptose gets second advance from Hanmi Pharmaceutical for Tuspetinib development in AML triplet therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 21:32:25 UTC 2629 followers, XXX engagements
"$AVXL Anavex Life Sciences reveals publication of Blarcamesine Phase IIb/III data in prestigious journal The Journal of Prevention of Alzheimer's Disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-01-15 12:32:08 UTC 2628 followers, XXX engagements
"Pharma/Biotech Highlights: $MNKD: MannKind expands patent portfolio with Clofazimine. $PHAT: FDA approves Phathom's Vonoprazan tablets. $BMY: EMA approves Bristol Myers Squibb's Opdivo. $DCPH: Positive Phase X results for Vimseltinib" @OzmosiHealth on X 2023-10-30 20:35:20 UTC 2623 followers, XXX engagements
"$ONCY TSX:ONC Oncolytics Biotech showcases translated data showing Pelareorep's effectiveness in various tumor types. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:03:32 UTC 2627 followers, XXX engagements
"$ELDN New findings from Eledon Pharmaceuticals' Phase 1b trial of Tegoprubart in kidney transplant patients will be shared at World Transplant Congress 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 20:32:55 UTC 2626 followers, XXX engagements
"$BCDA Henry Ford Health begins enrolling patients for BioCardia's CardiAMP HF II study for Ischemic Heart Failure with Reduced Ejection Fraction. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:03:34 UTC 2627 followers, XXX engagements
"Boehringer Ingelheim and LEO Pharma join forces to market and advance SPEVIGO (spesolimab) product. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:28 UTC 2627 followers, XXX engagements
"$OGEN Oragenics Inc. reveals drug manufacturing deal in the U.S. to aid ONP-002 clinical progress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:03:37 UTC 2627 followers, XXX engagements
"$ALDX Aldeyra Therapeutics' NDA for Reproxalap in treating Dry Eye Disease accepted by FDA for review. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:32:56 UTC 2626 followers, XXX engagements
"$CNTB Simcere Pharmaceutical Connect Biopharma's Exclusive Licensee in China has submitted a New Drug Application for Rademikibart to treat Atopic Dermatitis in China. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-09 14:02:23 UTC 2627 followers, XXX engagements
"$MRK Health Canada approved KEYTRUDA to treat adult patients with FIGO 2014 Stage III-IVA cervical cancer alongside chemoradiotherapy (CRT). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 15:32:12 UTC 2626 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials of Obefazimod in treating moderate-severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 01:32:42 UTC 2625 followers, XXX engagements
"$IVBIY In 2025 Innovent Biologics will present updated data on IBI363 (PD-1/IL-2-bias Bispecific Antibody Fusion Protein) in Phase X trials for advanced colorectal cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-02 00:32:48 UTC 2623 followers, XXX engagements
"$COCP Cocrystal Pharma will share Phase X study results for Norovirus Protease Inhibitor CDI-988 at 9th International Calicivirus Conference. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 12:32:29 UTC 2627 followers, XXX engagements
"$BIVI BioVie showcased data at the 2nd World Conference on Aging highlighting potential age deceleration with Bezisterim treatment compared to placebo on XX different biological clocks. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:38 UTC 2629 followers, XXX engagements
"$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-09 11:32:37 UTC 2629 followers, XXX engagements
"$AQST Aquestive Therapeutics announces update on international expansion for Anaphylm (epinephrine) Sublingual Film. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 11:02:21 UTC 2623 followers, XXX engagements
"Aicuris completed enrollment for pivotal trial of Pritelivir for refractory herpes simplex in immunocompromised patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 09:03:19 UTC 2630 followers, XXX engagements
"$CSE:HLUNA CSE:HLUNB CSE:LUN Lundbeck expands dose finding for Lu AG09222 in migraine prevention after planned analysis in PROCEED trial includes intravenous administration. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-03-31 20:02:59 UTC 2628 followers, XX engagements
"$SXTP SXTPW XX Degrees Pharmaceuticals and Tulane University collaborate for research on Tafenoquine against Lyme and Bartonella bacteria. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:27 UTC 2627 followers, XXX engagements
"FDA fast tracks Addyi for postmenopausal women with low sexual desire enabling quicker access to treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:35 UTC 2630 followers, XXX engagements
"$CSE:BETR BetterLife Pharma issues scientific update on neuroplastogenic activity of BETR-001. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-05-28 12:32:34 UTC 2628 followers, XXX engagements
"$KRYS Jeune reports successful Phase X results for KB304 in treating moderate to severe dcollet wrinkles with noticeable aesthetic improvements. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:43 UTC 2630 followers, XXX engagements
"$LTRN Lantern Pharma gets EU patent for LP-284 strengthening global IP for AI-designed cancer treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:19 UTC 2624 followers, XXX engagements
"Novartis reaches agreement with pan-Canadian Pharmaceutical Alliance on Cosentyx for hidradenitis suppurativa (HS) treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 18:32:25 UTC 2627 followers, XXX engagements
"$ARGX argenx progresses clinical development of ARGX-119 for Congenital Myasthenic Syndromes. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-30 05:32:38 UTC 2626 followers, XXX engagements
"$PARIS:AB AB Science has been approved by multiple European countries to begin phase X study on masitinib for ALS. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 06:02:16 UTC 2630 followers, XXX engagements
"$CGEN First patient dosed in COM701 Global Platform Trial for Platinum Sensitive Ovarian Cancer announced by Compugen. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:25 UTC 2626 followers, XXX engagements
"Ultomiris drug market projected to reach USD XXXXX billion by 2034 with a CAGR of 31.52%. Report covers analysis trends forecast segmentation growth rate and SWOT analysis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 04:32:29 UTC 2627 followers, XXX engagements
"$AVTE FNA RSLS Halper Sadeh LLC is conducting a shareholder investigation on behalf of shareholders for FNA AVTE RSLS. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-03-23 23:02:18 UTC 2625 followers, XXX engagements
"Akeso starts Phase III trial of Ivonescimab for Pancreatic Cancer with first patient enrollment announced. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 01:32:32 UTC 2630 followers, XXX engagements
"$IVBIY Phase X results of Innovent Biologics' IBI343 for advanced gastric/esophageal adenocarcinoma published in Nature Medicine. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 00:32:21 UTC 2625 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMAB I-Mab Biopharma will present Phase X Oncology Solid Tumor Unspecified Data for Givastomig (CLDN18.2 Inhibitor4-1BB Inhibitor - Bispecific Antibody) tomorrow 👀" @OzmosiHealth on X 2025-07-01 11:12:15 UTC 2627 followers, XXX engagements
"Revalesio will discuss Phase X trial design and post hoc analysis of Phase X RESCUE trial of RNS60 in acute ischemic stroke at SNIS 22nd Annual Meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 15:32:55 UTC 2627 followers, XXX engagements
"AGT announces promising results from AGT103-T HIV Functional Cure Program presented as late-breaker at International AIDS Society 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 15:32:26 UTC 2628 followers, XXX engagements
"$ATRA Pierre Fabre Pharmaceuticals Inc. reveals FDA acceptance and priority review of Biologics License Application for Tabelecleucel for EBV+ PTLD treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 13:02:20 UTC 2630 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod an oral miR-124 enhancer for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 02:02:42 UTC 2628 followers, XXX engagements
"$NBIX Neurocrine Biosciences reveals 1-year data demonstrating sustained effectiveness of CRENESSITY (crinecerfont) in adult patients at ENDO 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 13:02:23 UTC 2624 followers, XXX engagements
"Nxera Pharma to get $15M from Neurocrine Biosciences after dosing first patient in Phase X trial for NBI-1117568. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-02 23:32:24 UTC 2625 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports encouraging Phase X results from ABTECT trials on Obefazimod for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 21:02:48 UTC 2630 followers, 1494 engagements
"$SLS SELLAS achieves all main goals in Phase X trial of SLS009 for r/r AML and gets FDA approval for further study in first-line therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 12:02:41 UTC 2627 followers, XXX engagements
"$ABOS Acumen Pharmaceuticals to share findings on cost savings from pTau217 screening in the Phase X ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at AAIC 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 12:32:27 UTC 2627 followers, XXX engagements
"Nanoscope Therapeutics begins submitting BLA to FDA for MCO-010 the first gene-agnostic therapy for Retinitis Pigmentosa. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:33 UTC 2627 followers, XXX engagements
"$MIST Milestone Pharmaceuticals' response to the FDA CRL for CARDAMYST (etripamil) Nasal Spray has been accepted. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-11 10:32:25 UTC 2627 followers, XXX engagements
"Windward Bio begins global Phase X asthma trial for WIN378 an anti-TSLP monoclonal antibody with potential as long-acting and best-in-disease treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:02:26 UTC 2626 followers, XXX engagements
"Inotrem introduces revolutionary precision medicine approach for Nangibotide trials in septic shock treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:32:31 UTC 2626 followers, XXX engagements
"$RDHL FDA provides positive feedback on RedHill's pathway for approval of RHB-204 for Crohn's Disease a groundbreaking treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 13:32:20 UTC 2625 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results in ABTECT trials for Obefazimod in moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 00:02:13 UTC 2625 followers, XXX engagements
"$VSTM Fast track designation granted to Verastem Oncology for VS-7375 in treating KRAS G12D-mutated Pancreatic Cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:32:21 UTC 2630 followers, XXX engagements
"$DARE Encouraging Phase X results demonstrate the potential of Ovaprene as a hormone-free contraceptive. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 12:32:29 UTC 2627 followers, XXX engagements
"$ABBV AbbVie and Ichnos Glenmark Innovation (IGI) agree on exclusive global license for ISB 2001 a novel Trispecific Antibody targeting CD38 BCMA and CD3. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 12:32:31 UTC 2627 followers, XXX engagements
"$PARIS:AB AB Science has received approval from several European countries to begin the confirmatory phase X study with masitinib in ALS. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 07:32:29 UTC 2630 followers, XXX engagements
"$VIR First patient dosed in Phase X trial of EGFR-targeting VIR-5525 for solid tumors by Vir Biotechnology. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:45 UTC 2630 followers, XXX engagements
"$SXTP SXTPW ARAOKDA (tafenoquine) has an annual potential market size of $XXX million and cumulative sales of $XXX billion through patent expiration according to XX Degrees Pharmaceuticals. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 11:32:22 UTC 2627 followers, XXX engagements
"$BRCTF Lecanemab's drug discovery research receives 9th Bioindustry Award from Japan Bioindustry Association. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 08:02:15 UTC 2626 followers, XXX engagements
"Hengrui Pharma and Kailera Therapeutics announce successful results from Phase X obesity trial in China for HRS9531 a dual GLP-1/GIP Receptor Agonist. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 12:02:42 UTC 2627 followers, XXX engagements
"$IDYA IDEAYA Biosciences to present Phase X Clinical Trial of Neoadjuvant Darovasertib at ESMO 2025 for Primary Uveal Melanoma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 13:32:29 UTC 2630 followers, XXX engagements
"$NBIX Neurocrine Biosciences shares new data from KINECT-HD Study showing INGREZZA reduces disease burden in Huntington's Chorea. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-27 13:02:15 UTC 2624 followers, XXX engagements
"First patient dosed in Phase 1b/2a trial of Procizumab a monoclonal antibody targeting shock's biological driver. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 10:02:22 UTC 2626 followers, XXX engagements
"$CSE:HLUNA CSE:HLUNB CSE:LUN Lundbeck expands Lu AG09222 dose finding to intravenous administration for migraine prevention after PROCEED trial interim analysis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-03-31 21:33:10 UTC 2628 followers, XXX engagements
"$BIIB STOK Biogen and Stoke Therapeutics will share data on Zorevunersen for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 12:02:29 UTC 2622 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT trials using Obefazimod for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 23:02:21 UTC 2624 followers, XXX engagements
"$AZN Baxdrostat successfully met all main and additional goals in Phase III trial for uncontrolled or treatment resistant hypertension in patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:31 UTC 2627 followers, XXX engagements
"$SXTP SXTPW XX Degrees Pharmaceuticals plans to request MUMS designation from FDA in 2025 for Tafenoquine to treat Acute Canine Babesiosis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 20:32:24 UTC 2627 followers, XXX engagements
"$HALO DARZALEX Faspro approved by EU Commission for adult patients with Smouldering Multiple Myeloma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 16:02:22 UTC 2626 followers, XXX engagements
"DCA opens today to enhance Asia's data center network. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 10:32:17 UTC 2626 followers, XXX engagements
"$KMSTF NLSP NLS Pharmaceutics reports progress in iTOL-102 program as BIRD Foundation approves payment to Kadimastem and iTolerance for Type X Diabetes therapy development. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:33:02 UTC 2626 followers, XXX engagements
"miraDry receives EU MDR certification and expands indications for reducing sweat odor and hair in Europe. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 17:32:46 UTC 2627 followers, XXX engagements
"$HOTH Hoth Therapeutics partners with VA for GDNF research targeting obesity and fatty liver. Study underway comparing GDNF to Semaglutide. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:16 UTC 2630 followers, XXX engagements
"$ONCY TSX:ONC Key Opinion Leader Event sheds light on Pelareorep's promising data in pancreatic and gastrointestinal fields highlighting its future potential. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 14:02:38 UTC 2629 followers, XXX engagements
"$PMN U.S. FDA grants ProMIS Neurosciences Fast Track Designation for PMN310 in Alzheimer's Disease treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:18 UTC 2626 followers, XXX engagements
"$CADL Candel Therapeutics obtains EMA Orphan Designation for CAN-2409 for Pancreatic Cancer treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:37 UTC 2630 followers, XXX engagements
"Reunion Neuroscience reports publication of RE104 Phase X Data in The Journal of Clinical Psychopharmacology. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:12 UTC 2626 followers, XXX engagements
"First patient enrolled in Phase 2a trial of 4P004 by Moving Biotech for knee osteoarthritis. 4P004 is a potential first-in-class GLP-1 therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 05:02:16 UTC 2627 followers, XXX engagements
"$MRK FDA gives the go-ahead for Merck Animal Health's BRAVECTO QUANTUM (Fluralaner for Extended-Release Injectable Suspension). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 21:02:20 UTC 2627 followers, XXX engagements
"Genascence receives FDA approval for GNSC-001 as a Regenerative Medicine Advanced Therapy for Knee Osteoarthritis (OA) in the U.S. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:31 UTC 2627 followers, XXX engagements
"$RCKT RCKT stock plunges due to FDA Clinical Hold on RP-A501 trial sparking Class Action by Hagens Berman. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 19:32:49 UTC 2626 followers, XXX engagements
"$BCDA BioCardia wants to meet with Japan PMDA to talk about getting approval for CardiAMP Cell Therapy in Ischemic Heart Failure. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 13:32:27 UTC 2630 followers, XXX engagements
"Oak Hill Bio has published results of Rugonersen Phase X study in Nature Medicine. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-11 09:02:13 UTC 2627 followers, XXX engagements
"$GLUE Phase X study of MRT-8102 a NEK7-Directed Molecular Glue Degrader for treating inflammatory diseases begins with dosing of first subjects by Monte Rosa Therapeutics. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:28 UTC 2624 followers, XXX engagements
"$CASI CASI Pharmaceuticals names David Cory as CEO to lead U.S. company focusing on CID-103 clinical development a promising Anti-CD38 program. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 20:32:23 UTC 2625 followers, XXX engagements
"$AGEN GSK GSK's SHINGRIX now approved by US FDA in prefilled syringe. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:32:58 UTC 2626 followers, XXX engagements
"$ASND Updated Phase X results show continued positive response to TransCon PTH treatment for adults with hypoparathyroidism with benefits in biochemistries kidney function and quality of life. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 20:32:25 UTC 2626 followers, XXX engagements
"$RARE Health Canada approves Evkeeza (evinacumab) for children as young as X months with Homozygous Familial Hypercholesterolemia (HoFH). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 12:32:25 UTC 2627 followers, XXX engagements
"$RVMD Revolution Medicines announces publication in Science on Zoldonrasib a selective inhibitor for RAS(ON) G12D. Discovery and development detailed in peer-reviewed paper. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 20:02:22 UTC 2630 followers, XXX engagements
"$ALNY OXLUMO (lumasiran injection) is now reimbursed in Canada for treating Primary Hyperoxaluria Type X (PH1) in pediatric and adult patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-02 17:03:18 UTC 2627 followers, XXX engagements
"$PHGE BiomX starts Phase 2b trial for BX004 in Cystic Fibrosis patients first patient dosed successfully. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 13:02:26 UTC 2626 followers, XXX engagements
"KERENDIA (finerenone) approved by U.S. FDA to treat heart failure patients with LVEF XX% after Priority Review. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 06:32:23 UTC 2627 followers, XXX engagements
"$MDGL Madrigal Pharmaceuticals has been granted a new U.S. patent by the Patent and Trademark Office for Rezdiffra (Resmetirom). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:32:23 UTC 2627 followers, XXX engagements
"$ZVRA MIPLYFFA (arimoclomol) by Zevra Therapeutics will be highlighted in presentations at the National Niemann Pick Disease Foundation Conference. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-11 11:32:12 UTC 2627 followers, XXX engagements
"Government endorses SNB-101 as promising Small Cell Lung Cancer therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:32:24 UTC 2627 followers, XXX engagements
"$RARE Ultragenyx gets Breakthrough Therapy status for GTX-102 in Angelman Syndrome. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-27 12:32:25 UTC 2622 followers, XXX engagements
"Alzheon will share details on Valiltramiprosate/ALZ-801 at Alzheimer's conference in Toronto on July XX 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 10:32:22 UTC 2626 followers, XXX engagements
"$RVMD FDA grants Breakthrough Therapy Designation to Revolution Medicines' Elironrasib. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:26 UTC 2630 followers, XXX engagements
"Diakonos Oncology reports first patient dosed in Phase X trial of DOC1021 for Glioblastoma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:19 UTC 2627 followers, XXX engagements
"ReAlta Life Sciences releases data showing RLS-0071 decreases brain inflammation in preclinical hypoxic ischemic encephalopathy model. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:18 UTC 2626 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod in treating Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 22:32:19 UTC 2624 followers, XXX engagements
"$KROS Keros Therapeutics initiates Phase X RENEW Clinical Trial of Elritercept with first patient dosing announced. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:29 UTC 2627 followers, XXX engagements
"$KZR FDA lifted partial clinical hold on PORTOLA Phase 2a Trial of Zetomipzomib for Autoimmune Hepatitis by Kezar Life Sciences. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 21:02:20 UTC 2627 followers, XXX engagements
"Canada approves Blenrep combos for relapsed/refractory multiple myeloma treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 11:32:21 UTC 2630 followers, XXX engagements
"First patient dosed by OncoC4 with potential best-in-class PD-1/VEGF bispecific antibody AI-081 in Phase X of BIPAVE-001 trial for solid tumors in US. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:16 UTC 2626 followers, XXX engagements
"$CORT New Drug Application submitted by Corcept for Relacorilant intended for patients with Platinum-Resistant Ovarian Cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 12:32:26 UTC 2629 followers, XXX engagements
"$QDEL QuidelOrtho and BHLMANN Laboratories AG introduce FCAL Turbo and FPELA Turbo assays on Vitros Systems as a MicroTip Partnership Assay. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:30 UTC 2623 followers, XXX engagements
"Apnimed announces positive results from Phase X trial of AD109 showing potential as first oral pill for obstructive sleep apnea. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 10:32:27 UTC 2628 followers, XXX engagements
"$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 12:02:15 UTC 2626 followers, XXX engagements
"First patient dosed in Phase X trial of MOMA-341 a potent Werner Helicase Inhibitor by MOMA Therapeutics. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:33 UTC 2626 followers, XXX engagements
"$CSE:RVV RVVTF Revive Therapeutics updates focus on R&D activities for Bucillamine in treating infectious diseases and medical countermeasures. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-02-03 22:02:33 UTC 2628 followers, XXX engagements
"Ammonium Chloride Market projected to reach $XXXX billion by 2034. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 15:33:16 UTC 2627 followers, XXX engagements
"$OTLC SAPU Bioscience highlights study linking TGFB2 to survival in younger pancreatic cancer patients in peer-reviewed publication. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 01:32:51 UTC 2626 followers, XXX engagements
"$SILO Silo Pharma finishes dosing in safety study for PTSD drug SPC-15. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 13:03:35 UTC 2627 followers, XXX engagements
"$LSTA Lisata Therapeutics obtains new composition of matter patent for Certepetide strengthening its intellectual property portfolio. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 12:32:26 UTC 2627 followers, XXX engagements
"$SLDB FDA grants Fast Track Designation to Solid Biosciences for SGT-501 a first-of-its-kind gene therapy for CPVT. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:27 UTC 2629 followers, XXX engagements
"$KRRO KRRO-110 from Korro granted Orphan Drug Designation by European Medicines Agency. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:21 UTC 2625 followers, XXX engagements
"$RGNX REGENXBIO reports preclinical data showing benefits of new Microdystrophin in RGX-202 for Duchenne Muscular Dystrophy gene therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 16:02:20 UTC 2627 followers, XXX engagements
"Cloudbreak Pharma Inc. reports encouraging Phase X findings for CBT-004 in patients with Vascularized Pinguecula. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 00:32:11 UTC 2624 followers, XXX engagements
"$IDYA IDEAYA and Hengrui reveal IDE849 for IASLC 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 17:32:15 UTC 2630 followers, XXX engagements
"$TLSA Tiziana Life Sciences reveals immune system analysis of nasal Foralumab in patients with moderate Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:20 UTC 2625 followers, XXX engagements
"Revalesio has published results of RESCUE Phase X Trial evaluating RNS60 as additional therapy for Acute Ischemic Stroke in Stroke journal. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:15 UTC 2626 followers, XXX engagements
"Imugene reports high response rates in Phase 1b trial of Azer-cel CAR T for 3L+ DLBCL. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 05:02:15 UTC 2627 followers, XXX engagements
"$PFE ViiV Healthcare found that XX% of HIV patients new to treatment opt for long-acting injectables Vocabria + Rekambys over daily pills after fast viral suppression. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 14:02:20 UTC 2627 followers, XXX engagements
"$IMAB I-Mab acquires Bridge Health to enhance Givastomig IP portfolio. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:33:04 UTC 2626 followers, XXX engagements
"$SWTX European Commission conditionally approves EZMEKLY (mirdametinib) for treating NF1-PN in adult and pediatric patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 16:04:40 UTC 2628 followers, 1013 engagements
"$CELC First patient in Phase X VIKTORIA-2 trial of Gedatolisib for HR+/HER2Advanced Breast Cancer dosed by Celcuity as first-line treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 20:32:27 UTC 2630 followers, XXX engagements
"Polivy (polatuzumab vedotin) by Roche Canada is now publicly reimbursed in Quebec for first-line treatment of large B-cell lymphoma in adults. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 13:32:14 UTC 2627 followers, XXX engagements
"$ACET Adicet Bio dosed the first Systemic Sclerosis patient in Phase X trial of ADI-001 for Autoimmune Diseases. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:02:39 UTC 2630 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMAB I-Mab Biopharma will present Phase X Gastrointestinal Cancer Data for Givastomig (CLDN18.2 Inhibitor4-1BB Inhibitor - Bispecific Antibody) tomorrow 👀" @OzmosiHealth on X 2025-07-01 11:12:15 UTC 2627 followers, XXX engagements
"$CYBN Cybin approved by UK MHRA for EMBRACE study on CYB003 in treating Major Depressive Disorder. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:33:00 UTC 2626 followers, XXX engagements
"$AUTL European Marketing Authorization approved for Autolus Therapeutics' CAR T therapy AUCATZYL for adults (26+) with relapsed or refractory B-ALL. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:22 UTC 2626 followers, XXX engagements
"ANZUPGO Cream is the first FDA-approved treatment for moderate-to-severe Chronic Hand Eczema in adults. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 21:02:23 UTC 2629 followers, XXX engagements
"$ATRA Atara Biotherapeutics shares regulatory and business updates for Tab-cel also known as Tabelecleucel. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 12:32:28 UTC 2626 followers, XXX engagements
"$KALV KalVista Pharmaceuticals has received UK MHRA approval for EKTERLY (sebetralstat) the first and only oral on-demand treatment for Hereditary Angioedema. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 20:32:29 UTC 2627 followers, XXX engagements
"$REPL FDA issues Complete Response Letter to Replimune for RP1 Biologics License Application for Advanced Melanoma treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:14 UTC 2626 followers, 1181 engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-week induction trials of Obefazimod in treating moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 00:32:12 UTC 2624 followers, XXX engagements
"$PTGX Protagonist submits NDA for first Icotrokinra FDA approval aiming to revolutionize plaque psoriasis treatment for adults and adolescents. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:16 UTC 2627 followers, XXX engagements
"FDA grants Orphan Drug Designation to ImCheck's ICT01 for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 09:32:28 UTC 2626 followers, XXX engagements
"$ANNX Enrollment in pivotal Phase X ARCHER II trial of Vonaprument (formerly ANX007) for Dry AMD with Geographic Atrophy completed by Annexon. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:02:38 UTC 2630 followers, XXX engagements
"$CVRX CVRx reports positive update on Barostim outpatient payment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:30 UTC 2626 followers, XXX engagements
"$IONS New study in JACI In Practice shows how donidalorsen benefits HAE patients who switched from other treatments in Phase X OASISplus data. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:23 UTC 2626 followers, XXX engagements
"$TNXP Tonix Pharmaceuticals will present new data on Mpox and smallpox vaccine TNX-801 at Vaccine Congress 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 11:34:42 UTC 2629 followers, 3262 engagements
"$RHHBY Genentech updates on Astegolimab in COPD. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 05:32:10 UTC 2627 followers, XXX engagements
"$BIIB STOK Stoke Therapeutics and Biogen will present data on Zorevunersen an investigational medicine for Dravet syndrome at the EPNS Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 11:34:39 UTC 2622 followers, XXX engagements
"$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:31 UTC 2627 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials for ABTECT 8-week induction using Obefazimod for moderate to severe ulcerative colitis a first-of-its-kind oral miR-124 enhancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 21:32:29 UTC 2630 followers, XXX engagements
"$AAPG China NMPA approves Ascentage Pharma's Lisaftoclax a novel Bcl-2 inhibitor marking a new era in CLL/SLL treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 14:04:33 UTC 2627 followers, XXX engagements
"$CGTX Cognition Therapeutics releases study examining how Zervimesine shields neurons and synapses in Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:02:13 UTC 2626 followers, XXX engagements
"$IMAB I-Mab shows promising data on Givastomig in combo with immunotherapy in 1L gastric cancer patients at ESMO GI 2025. Phase 1b results are positive. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-02 15:32:30 UTC 2626 followers, XXX engagements
"$IVBIY Innovent initiates Phase X trial for IBI354 a new HER2 ADC in platinum-resistant ovarian cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-03-24 00:32:28 UTC 2627 followers, XXX engagements
"$IRON Disc Medicine confirms plan to submit NDA for Bitopertin in EPP in October 2025 after positive pre-NDA meeting announcement. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:14 UTC 2627 followers, XXX engagements
"$IMAB I-Mab releases Givastomig Monotherapy Data in Clinical Cancer Research. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-30 20:32:41 UTC 2628 followers, XXX engagements
"$ATYR aTyr Pharma reports completion of Phase X EFZO-FIT study of Efzofitimod in patients with pulmonary sarcoidosis. Last patient visit announced. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:02:11 UTC 2630 followers, XXX engagements
"tr Chitosan patents new USP inhalant product. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 19:02:23 UTC 2627 followers, XXX engagements
"Eisai to share four-year efficacy and safety results for continuous treatment with lecanemab at Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 00:02:41 UTC 2624 followers, XXX engagements
"$BMY Bristol Myers Squibb reports Phase X INDEPENDENCE Trial topline findings for Reblozyl in adults with Myelofibrosis-Associated Anemia. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 11:02:16 UTC 2623 followers, XXX engagements
"$RHHBY Genentech updates on FDA application for Columvi combo for patients with relapsed or refractory Diffuse Large B-cell Lymphoma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 16:04:42 UTC 2627 followers, 1684 engagements
"$RPTX Repare Therapeutics and Debiopharm have signed an exclusive global licensing deal for Lunresertib. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 20:32:27 UTC 2627 followers, XXX engagements
"$GILD Gilead shares new research on lenacapavir's effectiveness for HIV prevention at IAS 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 14:02:21 UTC 2623 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT 8-Week trial on Obefazimod for Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 22:02:19 UTC 2630 followers, XXX engagements
"$GMAB Genmab reports DARZALEX (daratumumab) net sales for Q2 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 10:32:18 UTC 2627 followers, XXX engagements
"Eisai will share four-year efficacy and safety data on continuous treatment with Lecanemab at the Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 08:02:08 UTC 2626 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 02:33:49 UTC 2624 followers, XXX engagements
"Long-acting fully human anti-TSLP antibody HBM9378/WIN378 enters global Phase X POLARIS trial for asthma treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 14:02:40 UTC 2626 followers, XXX engagements
"$ADAG Adagene provides regulatory update on clinical plan for Muzastotug in microsatellite stable colorectal cancer after successful FDA meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 11:02:20 UTC 2623 followers, XXX engagements
"Italfarmaco reveals new cardiac findings on Givinostat at 16th EPNS Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-11 08:32:21 UTC 2627 followers, XXX engagements
"$HIMS Securities class actions initiated against Hims & Hers Health Inc. (HIMS) for alleged deceptive marketing of Wegovy. Investors with losses urged to contact Hagens Berman. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 19:32:47 UTC 2623 followers, XXX engagements
"$UNCY Unicycive Therapeutics releases Oxylanthanum Carbonate trial results in Clinical Journal of the American Society of Nephrology. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:42 UTC 2630 followers, XXX engagements
"$OKYO OKYO Pharma secures $1.9M in non-dilutive funding to speed up Urcosimod development for Neuropathic Corneal Pain. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 13:02:45 UTC 2626 followers, XXX engagements
"ImCheck's ICT01 has received Orphan Drug Designation from the EMA for treating Acute Myeloid Leukemia. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:26 UTC 2626 followers, XXX engagements
"$ALMS Alumis finishes enrolling patients in global LUMUS Phase 2b trial of ESK-001 an advanced oral TYK2 inhibitor for treating Systemic Lupus Erythematosus. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:32:20 UTC 2630 followers, XXX engagements
"$OTLC Oncotelic Therapeutics points to study linking TGFB2 to survival in younger pancreatic cancer patients in new publication. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 15:32:19 UTC 2626 followers, XXX engagements
"$RCKT Rocket Pharmaceuticals gets FDA RMAT Designation for RP-A601 gene therapy for PKP2-Arrhythmogenic Cardiomyopathy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:33:06 UTC 2626 followers, XXX engagements
"AusperBio has obtained China CDE approval to progress AHB-137 to Phase III clinical trial for Chronic Hepatitis B treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 20:02:16 UTC 2624 followers, XXX engagements
"$ZVRA Zevra Therapeutics reveals data from open label extension proving MIPLYFFA's long-term effectiveness in treating NPC published in Journal of Molecular Genetics and Metabolism. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:26 UTC 2627 followers, XXX engagements
"$ATRA Pierre Fabre Pharmaceuticals Inc. moves Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics Inc. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 12:32:27 UTC 2627 followers, XXX engagements
"ORYZON is enhancing its patent portfolio for Vafidemstat. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 12:02:16 UTC 2627 followers, XXX engagements
"$LTRN Lantern Pharma announces full response in highly treated lymphoma patient with LP-284 in Phase X trial. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:02:16 UTC 2626 followers, XXX engagements
"Eolas Therapeutics now has complete control over the development of AZD4041. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 12:32:25 UTC 2627 followers, XXX engagements
"$KAPA Safety results from Phase X trial of ENV-105 in advanced prostate cancer by Kairos Pharma show positive outcomes. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 12:32:29 UTC 2627 followers, XXX engagements
"$TAK TYO:4502 Takeda reports positive outcomes from two Phase X trials of Oveporexton (TAK-861) in Type X Narcolepsy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 07:32:16 UTC 2627 followers, XXX engagements
"Spherix Global Insights reports GSK's Linerixibat set to help with unmet needs in treating pruritus linked to Primary Biliary Cholangitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 17:32:37 UTC 2623 followers, XXX engagements
"4TEEN4 reveals in European Journal of Heart Failure successful reversal of shock in first human trials using Procizumab in three compassionate cases. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 09:32:22 UTC 2627 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports promising Phase X findings on ABTECT 8-Week Induction Trials for Obefazimod an oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 20:34:09 UTC 2624 followers, 1002 engagements
"$AZN TAGRISSO combined with chemotherapy showed significant and meaningful enhancement in overall survival for EGFR-mutated advanced lung cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:18 UTC 2626 followers, XXX engagements
"$ENSC Ensysce Biosciences starts Phase X trial for PF614 a new opioid for pain relief with abuse deterrent properties. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:32:26 UTC 2627 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-Week Induction Trials of Obefazimod in patients with moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 23:32:13 UTC 2624 followers, XXX engagements
"$ENVB Enveric Biosciences gets second U.S. patent allowance for non-hallucinogenic mescaline derivatives in EVM401 Series. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:29 UTC 2628 followers, XXX engagements
"$PARIS:COX PARIS:FR Nicox and Kowa ink deal worth XXXXX million granting exclusive rights to Glaucoma Treatment NCX XXX in U.S. and unlicensed territories. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 05:32:24 UTC 2626 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 01:02:12 UTC 2625 followers, XXX engagements
"GenSight Biologics reports study results on factors predicting final visual outcome in patients who received LUMEVOQ gene therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 13:02:43 UTC 2627 followers, XXX engagements
"Akeso has enrolled the first patient in Phase III trial (AK112-312/HARMONi-GI6) for Ivonescimab in advanced metastatic colorectal cancer treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 02:02:20 UTC 2626 followers, XXX engagements
"$RYTM Rhythm Pharmaceuticals shares findings on MC4R agonists Setmelanotide and Bivamelagon at ENDO 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-12 22:02:14 UTC 2627 followers, XXX engagements
"$ENVB Enveric Biosciences' top drug candidate EB-003 shows promise in preclinical PTSD model with positive effects. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 13:32:18 UTC 2627 followers, 2751 engagements
"$CYTK Cytokinetics reveals five presentations on Aficamten at ESC Congress 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 11:34:37 UTC 2624 followers, XXX engagements
"$RCKT FDA Clinical Hold on RP-A501 Trial causes Rocket Pharmaceuticals (RCKT) stock to plummet and leads to Class Action lawsuit by Hagens Berman. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 22:34:28 UTC 2630 followers, XXX engagements
"Kelun-Biotech's partner Windward Bio starts global Phase X trial for SKB378/WIN378 in asthma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:32:32 UTC 2630 followers, XXX engagements
"$BRCTF New data on Lecanemab's effectiveness and safety over four years will be shared at AAIC 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 06:32:21 UTC 2626 followers, XXX engagements
"$ORKA Oruka Therapeutics gets IND clearance for EVERLAST-A Phase 2a trial of ORKA-001 in Psoriasis. Phase X data to be detailed at EADV in September. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:29 UTC 2627 followers, XXX engagements
"$OCGN First patient dosed in Phase 2/3 GARDian3 trial for OCU410ST a gene therapy candidate for Stargardt Disease announced by Ocugen Inc. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 11:32:19 UTC 2626 followers, 1236 engagements
"Alkeus Pharmaceuticals to present Gildeuretinol data at ASRS 43rd Annual Meeting on July 29-August X. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:24 UTC 2626 followers, XXX engagements
"$JNJ Johnson & Johnson aims for US FDA approval of icotrokinra to change treatment for adults and teens with plaque psoriasis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 13:02:14 UTC 2624 followers, XXX engagements
"Hillhurst Biopharmaceuticals administers first dose in Phase 2a trial for HBI-002 a new treatment for Sickle Cell Disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 20:02:34 UTC 2630 followers, XXX engagements
"$CMND CSE:CMND Clearmind Medicine finishes starting trial at top Israeli site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:02:24 UTC 2626 followers, XXX engagements
"$CELC Celcuity announces new patent for Gedatolisib extending exclusivity until 2042. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 11:32:24 UTC 2625 followers, XXX engagements